

DAFTAR PUSTAKA

- Ahmad AM, Akhtar S, Hasan R, Khan JA, Hussain SF, Rizvi N. 2012. *Risk factors for multidrug-resistant tuberculosis in urban Pakistan: A multicenter case-control study*. Int J Mycobacteriol ;1:137-42
- Asri, Sri Dhuny. 2014. *Masalah Tuberkulosis Resisten Obat*.
- A.Sanga. 2014. *Faktor yang Berhubungan dengan Kejadian TB Paru pada Usia Produktif di Balai Besar Paru Makassar. Makassar: Sekolah Tinggi Ilmu Kesehatan Makassar (STIK)*.
- Barroso, Elizabeth Clara, Mota, Rosa Maria Salani, Santos, Raimunda Oliveira, Sousa, Ana Lúcia Oliveira, Barroso, Joana Brasileiro, & Rodrigues, Jorge Luís Nobre. (2003). *Risk factors for acquired multidrug-resistant tuberculosis*. *Jornal de Pneumologia*, 29(2), 89-97. <https://dx.doi.org/10.1590/S0102-35862003000200008>
- Bloss E, Kukša L, Holtz TH, Riekstina V, Skripc̆onoka V, Kammerer S, dkk. *Adverse Events Related To Multidrug-Resistant Tuberculosis Treatment*, Latvia, 2000–2004. Int J Tuberc Lung Dis. 2010;14(3):275–81.
- Crofton J, Horne N, Miller F. (1998). *Tuberkulosis Klinik*. Penerjemah : Moeljono et al. Jakarta : Widya Medika.
- Depkes RI. 2011. *Pedoman Nasional Penanggulangan Tuberkulosis*. Jakarta: Depkes.
- Demile, B., Zenebu, A., Shewaye, H. et al. (2018) Risk factors associated with multidrug-resistant tuberculosis (MDR-TB) in a tertiary armed force referral and teaching hospital, Ethiopia. BMC Infect Dis 18, 249 doi:10.1186/s12879-018-3167-9
- Desissa, F., Workineh, T. & Beyene, T. (2018). *Risk factors for the occurrence of multidrug-resistant tuberculosis among patients undergoing multidrug-resistant tuberculosis treatment in East Shoa, Ethiopia*. BMC Public Health 18: 422. <https://doi.org/10.1186/s12889-018-5371-3>
- Elduma, A. H., Mansournia, M. A., Foroushani, A. R., Ali, H., Elegail, A., Elsony, A., & Holakouie-Naieni, K. 2019. Assessment of the risk factors associated with multidrug-resistant tuberculosis in Sudan: a case-control study. *Epidemiology and health* 41, e2019014. doi:10.4178/epih.e2019014

M. (2019). Finding New Ways to Combat Multidrug-Resistant Tuberculosis. *Global Drug Resistance*, 00(00), 1–10. <https://doi.org/10.1089/mdr.2018.0353>



- Faustini A, Hall AJ, Perucci CA. 2006. *Risk Factors For Multidrug Resistant Tuberculosis In Europe: A Systematic Review* *Thorax*; 61:158-163
- Fauziah, L., & Korib, M. (2013). Faktor-faktor yang Berpengaruh Terhadap Kejadian Tuberkulosis Multidrug Resistant (TB-MDR) di RSUP Persahabatan Tahun 2013. *Jurnal FKM UI*, 1–18.
- Ghajavand, H., Kargarpour Kamakoli, M., Khanipour, S., Pourazar Dizaji, S., Masoumi, M., Rahimi Jamnani, F., ... Vaziri, F. (2019). *Scrutinizing the drug resistance mechanism of multi- and extensively-drug resistant Mycobacterium tuberculosis: Mutations versus efflux pumps. Antimicrobial Resistance and Infection Control*, 8(1), 1–8. <https://doi.org/10.1186/s13756-019-0516-4>
- Glasauer, S., Altmann, D., Hauer, B., Brodhun, B., Haas, W., & Perumal, N. (2019). *First-line tuberculosis drug resistance patterns and associated risk factors in Germany, 2008-2017. PLoS ONE*, 14(6), 2008–2017. <https://doi.org/10.1371/journal.pone.0217597>
- Gomez-Gomez, A. Et Al. *Diabetes And Other Risk Factors For Multi-Drug Resistant Tuberculosis In A Mexican Population With Pulmonary Tuberculosis: Case Control Study. Archives Of Medical Research* 46, 142–148, Doi:10.1016/j.arcmed.2015.01.006 (2015).
- Gordin FM, Nelson ET, Matts JP, Cohn DL, Ernst J, et al. (1996) *The impact of human immunodeficiency virus infection on drug-resistant tuberculosis. Am J Respir Crit Care Med* 154: 1478–1483.
- Hamusse SD, Teshome D, Hussen MS, Demissie M, Lindtjørn B. 2016. *Primary and secondary anti-tuberculosis drug resistance in Hitossa District of Arsi Zone, Oromia regional state, Central Ethiopia. BMC Public Health*;16:593.
- Holtz Timothy H, Sternberg M, Kammerer S et al. (2006). *Time to sputum culture conversion in multidrug-resistant tuberculosis: Predictors and relationship to treatment outcome. Ann Intern Med*;144:650-9
- Hovhannesian A, Breeze E. (2012). *Time to sputum conversion in multidrug-resistant tuberculosis patients in Armenia: retrospective cohort study. GJMPH*;1:24-8.
- Jain A, Dixit P. (2008). *Multidrug Resistant to Extensively Drug Resistant Tuberculosis : What is Next?. J. Biosci.* 33(4): 605-606. 22 Desember 2012.
- JFJ, Dotulong dan Sapulete, MR dkk. 2015. *Hubungan Faktor Risiko Umur, Jenis Kelamin dan Kepadatan Hunian dengan Kejadian Penyakit TB Paru di Desa Wori Kecamatan Wori.*
- Johnson J, Kagal A, Bharadwaj. (2003). *Factors Associated with Drug Resistance in Primary Tuberculosis. Indian J Chest Dis Allied Sci.* 45: 105-109. 20 Desember



- Fattiyah I, Zubaedah T, Priyanti ZS, Erlina B, Reviono, Soedarsono, dkk, penyunting. *Tuberkulosis Pedoman Diagnosis dan Penatalaksanaan di Indonesia*. Edisi revisi pertama. Jakarta: PDPI; 2011.
- K, S. S., & Alladi, M. (2006). Multidrug-Resistant Tuberculosis. *CHEST*, 130(1), 261–272. [https://doi.org/10.1016/S0012-3692\(15\)50981-1](https://doi.org/10.1016/S0012-3692(15)50981-1)
- Kemendes RI. 2015. *Profil Kesehatan Indonesia Tahun*. Universitas Sam Ratulangi : Jurnal Kedokteran Komunitas dan Tropik.
- Kemendes Sulawesi Selatan. 2014. *Profil Kesehatan Provinsi Sulawesi Selatan*.
- Korua, Elisa S, Kapantaw dan Nova H dkk. 2014. *Hubungan antara Umur, Jenis Kelamin dan Kepadatan Hunian dengan Kejadian TB Paru pada Pasien Rawat Jalan di Rumah Sakit Umum Daerah Noongan*. Manado: FKM Sam Ratulangi: 2014.
- Mansjoer, Arief dkk. 2014. *Kapita Selekta Kedokteran*. Jakarta: Medica Aescupalus FKUI.
- Moore M, McCray E, Onorato IM (1999) *Cross-matching TB and AIDS registries: TB patients with HIV co-infection*, United States, 1993–1994. *Public Health Rep* 114: 269–277.
- Lin, M., Zhong, Y., Chen, Z., Lin, C., Pei, H., Shu, W., & Pang, Y. (2019). High incidence of drug-resistant Mycobacterium tuberculosis in Hainan Island, China . *Tropical Medicine & International Health*, 00(00), 1–6. <https://doi.org/10.1111/tmi.13285>
- Marahatta, S. (2010). *Multi-drug resistant tuberculosis burden and risk factors: An update*. Kathmandu University Medical Journal, 8(1). doi:10.3126/kumj.v8i1.3234
- Mondero I, Caminero JA. *Management of Multidrug Resistant Tuberculosis an Update*. *Ther Adv Respir Dis*. 2010;4(2):117–27.
- Muaz, Fariz. 2014. *Faktor-Faktor yang Mempengaruhi Kejadian Tuberkulosis Paru Basil Tahan Asam di Puskesmas Wilayah Kecamatan Serang Kota Serang tahun 2014*. Jakarta: Universitas Syarif Hidayatullah. Muhammad, Fadel dan Rahmanisa, Soraya. 2016. *Intervensi untuk Mencegah Tuberkulosis Resisten Obat*.
- Narasimhan, dkk. 2013. *Multifunctional nanoparticles for targeted delivery of immune activating and cancer therapeutic agents*.
- National Collaborating Center for Chronic Conditions 2006. *Clinical diagnosis and management of tuberculosis and measures for its prevention and control*. London: Royal College of Physicians.

S. 2010. *Metodologi Penelitian Kesehatan*. Jakarta: Rineka Cipta



- Panji U, Susan H dan Agung W. 2013. *Pembedahan untuk Extensively Drug Resistant Tuberculosis (XDR TB) dengan Perhatian Pencegahan Transmisi kepada Petugas Kesehatan di RSUP Persahabatan.*
- Park, H.-O., Kim, S.-H., Moon, S.-H., Byun, J.-H., Kim, J.-W., Lee, C.-E., ... Yang, J.-H. (2016). *Association between Body Mass Index and Sputum Culture Conversion among South Korean Patients with Multidrug Resistant Tuberculosis in a Tuberculosis Referral Hospital. Infection & Chemotherapy*, 48(4), 317. doi:10.3947/ic.2016.48.4.317
- Patel KB, Belmonte R, Crowe HM (1995) *Drug malabsorption and resistant tuberculosis in HIV-infected patients.* N Engl J Med 332: 336–337.
- Paula K, Mamah S dan Wartolah. 2014. *Stigma dan Diskriminasi Klien Tuberkulosis.*
- Perez-Navarro, L. M., Fuentes-Dominguez, F. J. & Zenteno-Cuevas, R. *Type 2 Diabetes Mellitus And Its Influence In The Development Of Multidrug Resistance Tuberculosis In Patients From Southeastern Mexico.* Journal Of Diabetes And Its Complications 29, 77–82, Doi:10.1016/J.jdiacomp.2014.09.007 (2015).
- Price, Sylvia A dan Wilson, Lorraine M. 2006. *Patofisiologi.* Jakarta: Interna Publishing.
- P. Ristyo Sari, dkk. 2012. *Hubungan Tingkat Sosial Ekonomi dengan Angka Kejadian TB Paru BTA Positif di Wilayah Kerja Puskesmas Peterongan Jombang Tahun 2012.*
- Quy HT, Buu TN, Cobelens FG, Lan NT, Lambregts CS, et al. (2006) *Drug resistance among smear-positive tuberculosis patients in Ho Chi Minh City, Vietnam.* Int J Tuberc Lung Dis 10: 160–166.
- Rifat M, Milton AH, Hall J, Oldmeadow C, Islam MA, Husain A, et al. (2014) *Development of Multidrug Resistant Tuberculosis in Bangladesh: A Case-Control Study on Risk Factors.* PLoS ONE 9(8): e105214. https://doi.org/10.1371/journal.pone.0105214
- Riskesda RI. 2013. *Pusat Data dan Informasi Kementerian Kesehatan RI.*
- Ruddy, M. (2005). *Rates of drug resistance and risk factor analysis in civilian and prison patients with tuberculosis in Samara Region, Russia.* Thorax, 60(2), 130–135. doi:10.1136/thx.2004.026922
- Rumende, C. M. (2018). *Risk Factors for Multidrug-resistant Tuberculosis.* 50(1), 1–2.
- Sastroasmoro. 2012. *Dasar-Dasar Metodologi Penelitian.* Jakarta: Sagung Seto

en dan Ilham, Much. 2016. *Evaluasi Program engendalian Tuberkulosis Drug Resistant (TB-MDR) dengan Strategi DOTS di Kabupaten Banyumas.*



- Sharma, D., Bisht, D., & Khan, A. (2018). *Potential Alternative Strategy against Drug Resistant Tuberculosis: A Proteomics Prospect*. *Proteomes*, 6(2), 26. <https://doi.org/10.3390/proteomes6020026>
- Sinaga, Bintang Yinke M. 2013. *Karakteristik penderita Multidrug Resistant Tuberculosis yang mengikuti Programmatic Management of Drug-Resistant Tuberculosis di Rumah Sakit Umum Pusat H. Adam Malik Medan*.
- Soepandi, Priyanti. 2014. *Hasil Pengobatan dan Variasi Biaya TB-MDR/XDR dengan Strategi PMDT di RSUP Persahabatan*.
- Sudoyo, Aru W, dan Bambang, Idrus Alwi dkk. 2009. *Buku Ajar Ilmu Penyakit Dalam*. Jakarta: Interna Publishing.
- Syafri, A. K. 2015. *Hubungan Kondisi Fisik Rumah Tuberkulosis Paru di Wilayah Puskesmas Ngemplak Boyolali*. Surakarta: Universitas Muhammadiyah Surakarta.
- Tabrani, Rab. 2013. *Ilmu Penyakit Paru*. Jakarta: TIM.
- Tembo, B. P. (2019). *Prevalence and factors associated with multidrug / rifampicin resistant tuberculosis among suspected drug resistant tuberculosis patients in Botswana*. 7, 1–8.
- Ullah, I., Javaid, A., Tahir, Z., Ullah, O., Shah, A. A., Hasan, F., & Ayub, N. (2016). *Pattern of Drug Resistance and Risk Factors Associated with Development of Drug Resistant Mycobacterium tuberculosis in Pakistan*. *PLOS ONE*, 11(1), e0147529. doi:10.1371
- Walker, I. F., Shi, O., Hicks, J. P., Elsey, H., Wei, X., Menzies, D., ... Newell, J. N. (2019). *Analysis of loss to follow-up in 4099 multidrug-resistant pulmonary tuberculosis patients*. *European Respiratory Journal*, 54(1). <https://doi.org/10.1183/13993003.00353-2018>
- Workicho, A., Kassahun, W., & Alemseged, F. (2017). *Risk factors for multidrug-resistant tuberculosis among tuberculosis patients: a case-control study*. *Infection and drug resistance*, 10, 91–96. doi:10.2147/IDR.S126274
- World Health Organization. (2008). *Guidelines for The Programmatic Management of Drug Resistant Tuberculosis. Emergency Update 2008*. Geneva: WHO Press.
- World Health Organization. (2015). *Global Tuberculosis Report*.
- World health Organization, (2007). *International Union Against Tuberculosis and Lung Disease A WHO/The Union Monograph on TB and Tobacco control, Joining to control two related global epidemics*. Geneva

Et Al. (2019). *Drug Non-Adherence And Reasons Among*



Multidrug-Resistant Tuberculosis Patients In Guizhou, China: A Cross-Sectional Study. Patient Preference And Adherence 2019:13 1641–1653.



Lampiran 1 Surat Rekomendasi Persetujuan Etik



KEMENTERIAN PENDIDIKAN DAN KEBUDAYAAN
UNIVERSITAS HASANUDDIN FAKULTAS KEDOKTERAN
KOMITE ETIK PENELITIAN KESEHATAN
RSPTN UNIVERSITAS HASANUDDIN
RSUP Dr. WAHIDIN SUDIROHUSODO MAKASSAR
Sekretariat : Lantai 2 Gedung Laboratorium Terpadu
JL.PERINTIS KEMERDEKAAN KAMPUS TAMALANREA KM.10 MAKASSAR 90245.



Contact Person: dr. Agussalim Bukhari, MMed, PhD, SpCK, TELP: 081241850858, 0411 5760003, Fax: 0411-581431

REKOMENDASI PERSETUJUAN ETIK

Nomor : 1186/UN4.6.4.5.31/ PP36/ 2019

Tanggal: 13 Desember 2019

Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

| | | | |
|--|---|--|---------------------------|
| No Protokol | UH19121097 | No Sponsor Protokol | |
| Peneliti Utama | Kurniawan Tri Jaya | Sponsor | |
| Judul Peneliti | Studi Deskriptif Faktor Resiko Terjadinya Resistensi OAT Terhadap Pasien MDR-TB di Rumah Sakit Wahidin Sudirohusodo Makassar dan Balai Besar Kesehatan Paru Masyarakat Makassar Periode Januari - Juni 2019 | | |
| No Versi Protokol | 1 | Tanggal Versi | 13 Desember 2019 |
| No Versi PSP | | Tanggal Versi | |
| Tempat Penelitian | RSUP dr. Wahidin Sudirohusodo Dan Balai Kesehatan Paru Masyarakat Makassar | | |
| Jenis Review | <input checked="" type="checkbox"/> Exempted <input type="checkbox"/> Expedited <input type="checkbox"/> Fullboard Tanggal | Masa Berlaku 13 Desember 2019 sampai 13 Desember 2020 | Frekuensi review lanjutan |
| Ketua Komisi Etik Penelitian Kesehatan FKUH | Nama Prof.Dr.dr. Suryani As'ad, M.Sc.,Sp.GK (K) | Tanda tangan | |
| Sekretaris Komisi Etik Penelitian Kesehatan FKUH | Nama dr. Agussalim Bukhari, M.Med.,Ph.D.,Sp.GK (K) | Tanda tangan | |

Kewajiban Peneliti Utama:

- Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan
- Menyerahkan Laporan SAE ke Komisi Etik dalam 24 Jam dan dilengapi dalam 7 hari dan Laporan SUSAR dalam 72 Jam setelah Peneliti Utama menerima laporan
- Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
- Menyerahkan laporan akhir setelah Penelitian berakhir
- Melaporkan penyimpangan dari protokol yang disetujui (protocol deviation / violation)
- Mematuhi semua peraturan yang ditentukan



Lampiran 2 Biodata Penulis

Nama : Kurniawan Tri Jaya

NIM : C111 16 038

Tempat, Tanggal Lahir : Padang-Padang, 7 Mei 1998

Jenis Kelamin : Laki-Laki

Agama : Islam

Alamat : Perumahan Azzahra Greenland D4, Daya

Alamat Surel : wawanmika@gmail.com

Riwayat Pendidikan :

1. TK Al-Azhar (2003-2004)
2. SD Negeri 27 Padang-Padang (2004-2010)
3. SMP Negeri 1 Bajo (2010-2013)
4. SMA Negeri 01 Unggulan Kamanre (2013-2016)
5. S1 Pendidikan Dokter Umum Fakultas Kedokteran Universitas Hasanuddin (2016–sekarang)

Pengalaman Organisasi :

1. Anggota Divisi Acara KEMA Fakultas Kedokteran Universitas Hasanuddin (2017)
2. Koordinator Divisi Operasional Bantuan Medis TBM Calcaneus Fakultas Kedokteran Universitas Hasanuddin (2018–2019)
3. Anggota Medical Muslim Family (2016-sekarang)

